Zentalis Pharmaceuticals’ (ZNTL) Neutral Rating Reiterated at Wedbush

Wedbush reiterated their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report sent to investors on Tuesday morning,RTT News reports. Wedbush currently has a $4.00 price objective on the stock. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.68) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at ($0.41) EPS and FY2029 earnings at $0.08 EPS.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen lowered Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Leerink Partners restated a “market perform” rating and set a $2.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday. Wells Fargo & Company reduced their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th. Finally, HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $5.03.

Zentalis Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ:ZNTL opened at $1.32 on Tuesday. The company has a market capitalization of $95.37 million, a price-to-earnings ratio of -0.64 and a beta of 1.87. The company has a 50 day moving average of $1.53 and a two-hundred day moving average of $1.45. Zentalis Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $4.16.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.12. On average, equities analysts anticipate that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd acquired a new position in Zentalis Pharmaceuticals in the second quarter valued at approximately $31,000. Cerity Partners LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 58.7% in the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after purchasing an additional 7,579 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Y Intercept Hong Kong Ltd bought a new position in Zentalis Pharmaceuticals during the 2nd quarter worth $38,000. Finally, Corient Private Wealth LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter worth $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.